HK1208225A1 - Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1 - Google Patents

Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1

Info

Publication number
HK1208225A1
HK1208225A1 HK15108922.9A HK15108922A HK1208225A1 HK 1208225 A1 HK1208225 A1 HK 1208225A1 HK 15108922 A HK15108922 A HK 15108922A HK 1208225 A1 HK1208225 A1 HK 1208225A1
Authority
HK
Hong Kong
Prior art keywords
positive allosteric
receptor positive
allosteric modulators
aryl methyl
methyl benzoquinazolinone
Prior art date
Application number
HK15108922.9A
Other languages
English (en)
Chinese (zh)
Inventor
Scott D Kuduk
Ronald K Chang
Thomas J Greshock
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HK1208225A1 publication Critical patent/HK1208225A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15108922.9A 2009-08-31 2015-09-11 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1 HK1208225A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23845709P 2009-08-31 2009-08-31

Publications (1)

Publication Number Publication Date
HK1208225A1 true HK1208225A1 (en) 2016-02-26

Family

ID=43628378

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108922.9A HK1208225A1 (en) 2009-08-31 2015-09-11 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1

Country Status (27)

Country Link
US (1) US8846702B2 (hr)
EP (2) EP2473048B1 (hr)
JP (1) JP5658255B2 (hr)
KR (1) KR101651312B1 (hr)
CN (1) CN102480964B (hr)
AU (1) AU2010286683B9 (hr)
BR (1) BR112012003464B8 (hr)
CA (1) CA2770480C (hr)
CO (1) CO6501188A2 (hr)
CY (1) CY1116452T1 (hr)
DK (1) DK2473048T3 (hr)
ES (1) ES2537979T3 (hr)
HK (1) HK1208225A1 (hr)
HR (1) HRP20150572T1 (hr)
HU (1) HUE026296T2 (hr)
IL (1) IL217638A (hr)
ME (1) ME02151B (hr)
MX (1) MX2012002583A (hr)
MY (1) MY160075A (hr)
NZ (1) NZ598462A (hr)
PL (1) PL2473048T3 (hr)
PT (1) PT2473048E (hr)
RS (1) RS54051B1 (hr)
RU (1) RU2507204C2 (hr)
SI (1) SI2473048T1 (hr)
WO (1) WO2011025851A1 (hr)
ZA (1) ZA201201205B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2512243T3 (pl) 2009-12-17 2016-09-30 Pozytywne modulatory allosteryczne receptora amidu chinoliny m1
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
EP2582241B1 (en) 2010-06-15 2016-04-06 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
WO2012003147A1 (en) 2010-07-01 2012-01-05 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
EP2709624B1 (en) * 2011-05-17 2016-04-27 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
EP2921480B1 (en) 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
PE20180500A1 (es) 2015-06-26 2018-03-09 Takeda Pharmaceuticals Co Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1
DK3347349T3 (da) * 2015-09-10 2019-10-28 Suven Life Sciences Ltd Fluorindolderivater som muskarin m1-receptor-positive allosteriske modulatorer
JP6787913B2 (ja) * 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
WO2017151449A1 (en) * 2016-03-04 2017-09-08 Merck Sharp & Dohme Corp. M1 receptor positive allosteric modulator compounds and methods of use thereof
JP7145875B2 (ja) * 2017-04-18 2022-10-03 武田薬品工業株式会社 アセチルコリン受容体のモジュレーターとして有用な複素環化合物
CN112752760B (zh) 2018-09-28 2024-01-19 武田药品工业株式会社 杂环化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
CA2220509C (en) 1995-05-31 2005-07-05 Eisai Co., Ltd. Fused polycyclic heterocycle derivatives
OA11877A (en) 1999-04-30 2006-03-29 Pfizer Prod Inc Glucocorticoid receptor modulators.
WO2001087845A2 (en) * 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
US20060233843A1 (en) 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
US8178667B2 (en) * 2006-06-28 2012-05-15 Merck Sharp & Dohme Corp. Benzyl-substituted quinolone M1 receptor positive allosteric modulators
AU2007275696B2 (en) 2006-07-17 2011-11-10 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
NZ584425A (en) * 2007-09-26 2012-03-30 Celgene Corp 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US8557832B2 (en) * 2008-11-20 2013-10-15 Merck Sharp & Dohme Corp. Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators
US8486946B2 (en) 2009-02-23 2013-07-16 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators
EP2421366B1 (en) 2009-04-20 2013-08-28 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
US8426438B2 (en) 2009-10-01 2013-04-23 Merck Sharp & Dohme Corp. Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators
EP2490692B1 (en) 2009-10-21 2016-11-16 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
US8664387B2 (en) 2009-12-14 2014-03-04 Merck Sharp & Dohme Corp. Pyridoquinazolinone M1 receptor positive allosteric modulators
GB0921949D0 (en) 2009-12-16 2010-02-03 Fujifilm Mfg Europe Bv Curable compositions and membranes
WO2011137049A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
ES2537979T3 (es) 2015-06-16
ZA201201205B (en) 2013-04-24
AU2010286683B2 (en) 2014-08-07
MX2012002583A (es) 2012-04-02
EP2473048B1 (en) 2015-03-25
KR20120073211A (ko) 2012-07-04
EP2915812A1 (en) 2015-09-09
JP2013503177A (ja) 2013-01-31
CA2770480C (en) 2014-11-18
DK2473048T3 (en) 2015-06-29
BR112012003464B8 (pt) 2021-05-25
BR112012003464B1 (pt) 2020-09-01
RU2507204C2 (ru) 2014-02-20
MY160075A (en) 2017-02-15
JP5658255B2 (ja) 2015-01-21
KR101651312B1 (ko) 2016-08-25
CO6501188A2 (es) 2012-08-15
CN102480964B (zh) 2015-07-08
EP2473048A1 (en) 2012-07-11
CA2770480A1 (en) 2011-03-03
PT2473048E (pt) 2015-07-02
BR112012003464A2 (pt) 2015-09-08
PL2473048T3 (pl) 2015-08-31
CN102480964A (zh) 2012-05-30
HUE026296T2 (en) 2016-06-28
CY1116452T1 (el) 2017-03-15
EP2473048A4 (en) 2013-02-13
US20120157438A1 (en) 2012-06-21
RS54051B1 (en) 2015-10-30
SI2473048T1 (sl) 2015-06-30
US8846702B2 (en) 2014-09-30
AU2010286683A1 (en) 2012-03-08
NZ598462A (en) 2012-12-21
RU2012112064A (ru) 2013-10-10
IL217638A (en) 2016-08-31
AU2010286683B9 (en) 2014-09-04
HRP20150572T1 (en) 2015-07-03
WO2011025851A1 (en) 2011-03-03
ME02151B (me) 2015-10-20

Similar Documents

Publication Publication Date Title
HK1208225A1 (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators m1
ZA201103612B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EP2490692A4 (en) COMPOUNDS OF QUINOLÉINONE-PYRAZOLONE POSITIVE ALLOSTERIC MODULATORS OF THE M1 RECEPTOR
HK1232219A1 (zh) 作為趨化因子受體調節劑的硫衍生物
EP2588104A4 (en) POSITIVE ALLOSTERIC MODULATORS OF ISOINDOLONE M1 RECEIVER
EP2512245A4 (en) POSITIVE ALLOSTERIC MODULATORS OF PYRIDOQUINAZOLINONE M1 RECEPTORS
EP2624697A4 (en) POSITIVE ALLOSTERIC DIHYDROBENZOCHINAZOLINONE M1 RECEPTOR MODULATORS
EP2501231A4 (en) POSITIVE ALLOSTERIC MODULATORS OF THE QUINOLIZIDINONE-CARBOXAMIDE TYPE M1 RECEPTOR
EP2515656A4 (en) POSITIVE ALLOSTERIC AMINOBENZOCHINAZOLINONE M1 RECEPTOR MODULATORS
HK1170122A1 (zh) 喹啉酰胺 受體陽性的别構調節劑
EP2244577A4 (en) POSITIVE ALLOSTERIC MODULATORS OF M1 RECEIVER OF QUINOLIZIDINONE TYPE
EP2312949A4 (en) POSITIVE ALLOSTERIC MODULATORS OF M1 N-HETEROCYCLIC RECEPTOR
HK1171449A1 (en) Morpholinothiazoles as alpha positive allosteric modulators
EP2582241A4 (en) HETEROCYCLIC FUSIONED PHENANTHROLINONE COMPOUNDS USEFUL AS POSITIVE ALLOSERIC MODULATORS OF THE M1 RECEPTOR
ZA201404270B (en) Dosage regimen of an s1p receptor modulator
EP2252151A4 (en) POSITIVE ALLOSTERIC CHINOLIZIDINONE M1 RECEPTOR MODULATORS
EP2421366A4 (en) POSITIVE ALLOSTERIC MODULATORS OF A HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR
GB201004739D0 (en) Receptor modulators
EP2563126A4 (en) POSITIVE ALLOSTERIC MODULATORS OF M1 RECEPTOR DERIVED FROM HETEROCYCLIC QUINOLIZINE
EP2709451A4 (en) POSITIVE ALLOSTERIC N-NETWORKED LACTAM M1 RECEPTOR MODULATORS
EP2709621A4 (en) POSITIVE ALLOSERIC MODULATORS OF M1 RECEPTOR TO QUINOLINE-AMIDE N-BINDING
EP2355659A4 (en) M1 RECEPTOR MODULATORS CONCEALED HETEROCYCLIC POSITIVE ALLOSTERIC
ZA201303950B (en) Glucagon receptor modulators
EP2252299A4 (en) CONDENSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
EP2340247A4 (en) POSITIVE ALLOSTERIC MODULATORS OF THE CHINOLIZIDINONE M1 RECEPTOR